Intellia Therapeutics (NASDAQ: NTLA) reported Q4 EPS of ($1.09), $0.15 worse than the analyst estimate of ($0.94). Revenue for the quarter came in at $12.9 million versus the consensus estimate of $8.26 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.